Cytochrome P450 IID6 has got typical features (genetical polymorphism,
competitive inhibition, saturability) which cart be at tile origin of
pharmacokinetic modifications of molecules using it for their metabol
ism. In the field of pharmacology, many molecules are substrates or in
hibitors of this cytochrome. They are presented. The results of a stud
y of the dextromethorphan variation test performed before and after 28
days of clomipramine therapy with depressed patients are explained. T
hey show a significant decreasing of the cytochrome P450 IID6 oxydatio
n capacities between both of these times. A patient has passed from th
e phenotype <<effective metabolizer>> to the one of <<poor metabolizer
>> with clomipramine.